Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$15.7K Buy
4,002
+1,449
+57% +$4.19K ﹤0.01% 8106
2025
Q4
$4.83K Sell
2,553
-253
-9% -$467 ﹤0.01% 8773
2025
Q3
$5.58K Buy
+2,806
New +$5.74K ﹤0.01% 8853
2024
Q3
Sell
-164
Closed -$502 9445
2024
Q2
$502 Sell
164
-250
-60% -$670 ﹤0.01% 8896
2024
Q1
$1.16K Buy
414
+413
+41,300% +$1.29K ﹤0.01% 8209
2023
Q4
$2 Buy
+1
New +$2 ﹤0.01% 9186
2021
Q4
Sell
-1,225
Closed -$18K 10212
2021
Q3
$18K Sell
1,225
-837
-41% -$13.7K ﹤0.01% 7265
2021
Q2
$28K Buy
2,062
+1,785
+644% +$24.8K ﹤0.01% 6998
2021
Q1
$5K Buy
+277
New +$6.31K ﹤0.01% 8299

Other funds holding ADAG

UBS Group's ADAG Position: Q1 2026 in Review

UBS Group increased its Adagene (ADAG) stake by 57% in Q1 2026, buying an estimated $4.19K and bringing the position to 4,002 shares worth $15.7K. The position accounts for ﹤0.01% of the portfolio, ranked #8106.

UBS Group first reported a position in ADAG in Q1 2021 and has held it in 9 quarters since. The position peaked at $28K in Q2 2021. 25 funds tracked by Wall St. Rank hold ADAG as of Q1 2026.

  • UBS Group held 4,002 shares of Adagene worth $15.7K as of Q1 2026.
  • UBS Group bought 1,449 Adagene shares in Q1 2026, an estimated $4.19K.
  • Adagene made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #8106 holding.
  • UBS Group first reported a position in Adagene in Q1 2021 and has held it in 9 quarters since.
  • UBS Group's Adagene position peaked at $28K in Q2 2021.
  • 25 funds tracked by Wall St. Rank held Adagene as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.